{"id":5899,"date":"2023-06-08T15:02:01","date_gmt":"2023-06-08T13:02:01","guid":{"rendered":"https:\/\/hemerapharma.com\/?p=5899"},"modified":"2025-06-19T20:48:08","modified_gmt":"2025-06-19T18:48:08","slug":"hemera-receives-orphan-drug-designation-remast","status":"publish","type":"post","link":"https:\/\/hemerapharma.com\/en\/hemera-receives-orphan-drug-designation-remast\/","title":{"rendered":"Hemera Receives Orphan Drug Designation for REMaST\u00ae Therapy"},"content":{"rendered":"
\n

REMaST\u00ae Recognized as an Orphan Drug for Acute Spinal Cord Injuries<\/strong><\/h2>\n
\n
\n
\n
\n
\n
\n
\n
\n

The advanced cell therapy REMaST\u00ae<\/a>, developed by Hemera, has been granted orphan drug designation by the European Commission<\/a> for the treatment of acute spinal cord injuries. This important recognition highlights the significance of the results achieved so far and the high therapeutic potential for patients suffering from severe and debilitating spinal cord injuries, for which no alternative treatments currently exist.<\/p>\n

The orphan drug designation (ODD) paves the way for an accelerated development pathway over the coming years, offering patients a concrete hope of regaining autonomy. Hemera will be supported by the European Medicines Agency (EMA) in the next steps toward marketing authorization with market exclusivity.<\/p>\n

We are proud to share this major milestone in our journey and extend our heartfelt thanks to the exceptional team<\/a> that works every day with skill and passion to bring the REMaST\u00ae therapy to patients as soon as possible.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/article>\n","protected":false},"excerpt":{"rendered":"

The advanced cell therapy REMaST\u00ae, developed by Hemera, has been granted orphan drug designation by the European Commission for the treatment of acute spinal cord injuries<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[31,32],"tags":[],"class_list":["post-5899","post","type-post","status-publish","format-standard","hentry","category-news-en","category-press-releases"],"acf":[],"_links":{"self":[{"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/posts\/5899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/comments?post=5899"}],"version-history":[{"count":1,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/posts\/5899\/revisions"}],"predecessor-version":[{"id":5900,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/posts\/5899\/revisions\/5900"}],"wp:attachment":[{"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/media?parent=5899"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/categories?post=5899"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/tags?post=5899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}